Image by Игорь Левченко from Pixabay

The munKNEE Pure-Play Marijuana-Based & Psychedelic Compounds-Based Drug Stocks Index consists of 8 constituents in each of the munKNEE Pure-Play Marijuana-Based Drug Stocks Index and the munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index. Which out-performed last week? This article has the answer. Here are the details:

One hundred clinical-stage psychedelic drug stocks now trade on North American stock exchanges. Sixty of the stocks research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances (read 10 Psychedelic Substances And The 35 Companies Researching Them) and 40 research the treatment of illnesses based on the use of THC marijuana (read Marijuana Drug Stocks: All You Need To Know).

The criteria for inclusion in the munKNEE Pure-Play Marijuana-Based & Psychedelic Compounds-Based Drug Stocks Index is that its constituents have market capitalizations in excess of $50M but less than $500M and only 16 of the 100 psychedelic drug stocks meet that criteria. The remaining 84 stocks in the Index have market caps below $50M or are above $500M. The latter include ATAI, Compass Pathways, Mind Medicine, and GH Resources and they are not included in the index given their very large market caps and high share prices which would have dominated the index's performance. (All currency amounts are in U.S. dollars. Go here to convert to another currency.)

The Pure-Play Marijuana-Based Drug Stocks Category

The 8 marijuana-based clinical-stage stocks

• were DOWN -14.2% last week and
• are now UP +12.2% YTD,
• ranged in price from $0.03/share to $4.47/share (an average of $1.44/share) as of Friday,
• and have an average market capitalization of approximately $104M.

Those that changed in price by +/- 5% last week are presented below in descending order including YTD percentage movements:

1. Allied Corp. (ALID): was UP +52.2% last week and is now UP +129.3% YTD
   • announced that it has initiated the manufacturing activities for Psilonex™ RX – Allied’s proprietary psilocybin product - under its manufacturing agreement with HAVN Life Sciences.
2. Enveric (ENVB): was UP +31.2% but is still DOWN -19.0% YTD
   • ​​​​​​​no specific news was attributed the gain in price
3. Revive (RVVTF): was UP +21.2% but is still DOWN -18.4% YTD
   • ​​​​​​​announced the purchase of the intellectual property pertaining to psilocybin from PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) for $7M plus up to an additional $3M in either cash or securities in the capital of Revive if future milestones are achieved.

The Pure-Play Psychedelic Compounds-Based Drug Stocks Category

The 8 psychedelic compound-based clinical-stage stocks

• were DOWN -0.2% last week but are still UP +51.6% YTD
• range in price from $0.18/share to $5.75/share (an average of $1.72/share) as of last Friday,
• and have an average market capitalization of $200M.

Those that changed in price by +/- 5% last week are presented below in descending order including YTD percentage movements. No specific news can be attributed to the changes in stock prices.

1. Awakn Life (AWKNF): was UP +6.3% last week but is still DOWN -22.0% since beginning to trade on June 23rd
2. Numinus (LKYSF): was DOWN -5.8% and is now DOWN -22.6% YTD
3. Small Pharma (DMTTF): was DOWN -5.9% and is now DOWN -11.1% YTD
4. Cybin (CYBN): was DOWN -8.3% but is still UP +61.3% YTD
5. Field Trip (FTRPF): was DOWN -11.8% but is still UP +56.0% YTD
6. Mydecine (MYCOF​​​​​​​): was DOWN -13.5% and is now DOWN -8.6% YTD

In Summary

In answer to the opening question as to which Index out-performed last week the answer is:

• the Marijuana-Based Drug Stocks Index was UP +14.2% last week and is now UP 12.2% YTD
• the Psychedelic Compounds-Based Index was DOWN -7.0% last week but is still UP +38.2% YTD

In combined total:

• the munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index was UP +2.0% last week and is now UP +23.4% YTD